OCT Europe: Small and mid-sized sponsors demand smart and reliable partnerships
One of the key challenges in clinical trial operations today is maintaining a trustworthy and reliable relationship with partners, vendors, …
Post
-
-
Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the …
-
First subject enrolled in BioCardia’s Phase III heart failure therapy trial
BioCardia has announced the enrolment of the first subject in the randomised, double-blind, placebo-controlled Phase III CardiAMP heart failure (HF) …
-
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops
Design Therapeutics has reported positive outcomes from the double-masked, randomised Phase I trial of its GeneTAC small molecule, DT-168, in …
-
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials. Breztri met primary …
-
IRT/RTSM: Key factors you need to know before choosing a solution for your trial
Melissa Peirsel is the Manager of IRT Services at Sharp and brings over 13 years of experience in clinical trial …
-
Tempus selects TIME Network for Phase I clinical trials
Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation …
-
Immunic presses ahead with MS drug despite Phase II endpoint miss
Immunic will continue developing its multiple sclerosis (MS) drug, vidofludimus calcium (IMU-838), despite a Phase II trial missing its primary …
-
Ultra-processed food consumption risks early death in lower income groups
Ultra-processed foods (UPFs) are a dominant part of the global food industry. UPFs are energy-dense, nutritionally unbalanced foods that contain …
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in …
-
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment
Rein Therapeutics has announced a partnership to integrate UK-based core imaging laboratory Qureight’s deep-learning platform into the upcoming Phase II trial …
-
End-to-end solutions: why every link in the pharmaceutical supply chain counts
Every stage of the pharmaceutical supply chain is critical if life-saving drugs are to make it to market – and …
-
Neurocrine begins Phase III programme for schizophrenia treatment
Neurocrine Biosciences has commenced a Phase III registrational programme to assess investigational oral muscarinic M4 selective orthosteric agonist NBI-1117568 as …
-
Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment
Amylyx Pharmaceuticals has dosed the first subject in the randomised Phase III LUCIDITY trial of glucagon-like peptide-1 (GLP-1) receptor antagonist …
-
Charting success through uncertainty in AI clinical trial implementation
Artificial Intelligence (AI) can augment productivity in clinical trial delivery and more, says Piotr Maslak, Director of Operational Data Intelligence …
